seribantumab
elevation oncology
['seribantumab']
#asco22 seribantumab in pts with #nrg1 fusion cancers showed rr 33% (including 17% cr) with 92% disease control rate. efficacy seen across fusion partners. responses occurred early. median dor not reached (75% of responders still on therapy). i find these extremely impressive. 
Director of Thoracic Oncology & Developmental Therapeutics @LombardiCancer, Associate Professor @Georgetown University #LCSM #HereWeGo #ITYSL He/Him